<DOC>
	<DOCNO>NCT01000688</DOCNO>
	<brief_summary>Rationale : Cardiovascular complication type 2 diabetes lead cause morbidity mortality associate disease . Endothelial dysfunction regard important factor vascular complication . The introduction glucagon-like peptide-1 ( GLP-1 ) analogues dipeptidyl peptidase IV ( DPP-IV ) inhibitor treatment type 2 diabetes special interest possible influence endothelial function . Numerous report show GLP-1 improves endothelial function . Objective : To determine whether four week treatment vildagliptin compare acarbose improves endothelial dysfunction patient type 2 diabetes mellitus .</brief_summary>
	<brief_title>Vildagliptin Endothelium-dependent Vasodilatation</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Acarbose</mesh_term>
	<criteria>Type 2 diabetes Age 3575 year Treatment metformin monotherapy metformin combination therapy HbA1c &lt; 8.0 % Renal disease define creatinine level &gt; 130 umol/l Liver disease define aspartate aminotransferase alanine aminotransferase level three time upper limit normal range Current use acetylsalicylic acid vitamine K antagonists History smoking within past year History current abuse drug alcohol History heartfailure ( NYHA class III IV ) Abnormalities ECG might interfere current study protocol Pregnancy breastfeed Inability understand nature extent trial procedure require Presence medical condition might interfere current study protocol Participation drug trial within 60 day prior first dose</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>